Lixte Biotechnology (NASDAQ:LIXT) Shares Up 3.4%

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT)’s share price shot up 3.4% during trading on Thursday . The stock traded as high as $3.05 and last traded at $3.00. 15,229 shares were traded during trading, a decline of 83% from the average session volume of 89,974 shares. The stock had previously closed at $2.90.

Lixte Biotechnology Price Performance

The company has a 50 day moving average price of $2.45 and a 200 day moving average price of $3.92. The firm has a market cap of $6.75 million, a PE ratio of -0.91 and a beta of -0.39.

Insider Transactions at Lixte Biotechnology

In other news, CEO Der Baan Bastiaan Jeroen Van purchased 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 3rd. The stock was purchased at an average cost of $2.80 per share, with a total value of $28,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 11,000 shares of the company’s stock, valued at approximately $30,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 15.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. EP Wealth Advisors LLC purchased a new position in Lixte Biotechnology in the first quarter valued at about $31,000. Renaissance Technologies LLC purchased a new position in shares of Lixte Biotechnology in the second quarter valued at $43,000. Finally, Geode Capital Management LLC increased its position in shares of Lixte Biotechnology by 292.4% in the first quarter. Geode Capital Management LLC now owns 101,209 shares of the company’s stock valued at $84,000 after buying an additional 75,415 shares in the last quarter. 11.85% of the stock is owned by hedge funds and other institutional investors.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development.